MARKET

RARE

RARE

Ultragenyx Pharm
NASDAQ
34.72
-0.68
-1.92%
After Hours: 34.72 0 0.00% 16:36 05/14 EDT
OPEN
35.43
PREV CLOSE
35.40
HIGH
36.03
LOW
34.47
VOLUME
580.96K
TURNOVER
--
52 WEEK HIGH
60.37
52 WEEK LOW
29.59
MARKET CAP
3.28B
P/E (TTM)
-5.9042
1D
5D
1M
3M
1Y
5Y
1D
Bank of America Securities Reaffirms Their Buy Rating on Ultragenyx Pharmaceutical (RARE)
TipRanks · 2h ago
Ultragenyx Underscores Continued Commitment to Rare Disease Innovation with 2024 Impact Report
Barchart · 13h ago
Weekly Report: what happened at RARE last week (0505-0509)?
Weekly Report · 2d ago
Ultragenyx Pharma Price Target Raised to $65.00/Share From $64.00 by Morgan Stanley
Dow Jones · 5d ago
Ultragenyx Pharma Is Maintained at Overweight by Morgan Stanley
Dow Jones · 5d ago
Morgan Stanley Maintains Overweight on Ultragenyx Pharmaceutical, Raises Price Target to $65
Benzinga · 5d ago
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates
Simply Wall St · 5d ago
Trump administration seeks tariff reductions and rare earths concessions in China talks - report
Seeking Alpha · 5d ago
More
About RARE
More
Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of novel products for the treatment of serious rare and ultrarare genetic diseases. Its therapies and clinical-stage pipeline consist of four product categories: biologics, small molecules, AAV gene therapy, and nucleic acid product candidates. Its four approved product candidates include Crysvita (burosumab) for the treatment of X-linked hypophosphatemia (XLH), and tumor-induced osteomalacia (TIO), Mepsevii (vestronidase alfa) for the treatment of mucopolysaccharidosis VII (MPSVII) or Sly Syndrome, Dojolvi (triheptanoin) for the treatment of long-chain fatty acid oxidation disorders (LC-FAOD), and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia (HoFH). Its clinical product candidates include DTX401, DTX301, UX701, UX143, UX111, and GTX-102. UX143 for the treatment of Osteogenesis Imperfecta.
Recently
Symbol
Price
%Change

Webull offers Ultragenyx Pharmaceutical Inc stock information, including NASDAQ: RARE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RARE stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading RARE stock methods without spending real money on the virtual paper trading platform.